Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TENUATE DOSPAN vs BONTRIL PDM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Releases norepinephrine from nerve terminals in the lateral hypothalamic feeding center, reducing appetite.
Phentermine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the release of norepinephrine and dopamine in the hypothalamus, reducing food intake. Topiramate is a sulfamate-substituted monosaccharide that enhances GABAergic activity and inhibits glutamatergic neurotransmission via AMPA/kainate receptors, leading to appetite suppression and increased energy expenditure.
Short-term adjunct in exogenous obesity,FDA-approved for obesity management
FDA-approved: Chronic weight management (BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity) as an adjunct to a reduced-calorie diet and increased physical activity.,Off-label: None widely recognized.
25 mg orally three times a day, 1 hour before meals, or 75 mg extended-release orally once daily in the morning.
Oral: 5-10 mg once daily in the morning; maximum 20 mg/day. Oral disintegrating tablet: 5-10 mg once daily.
The terminal elimination half-life is approximately 4-6 hours in adults with normal renal function, though clinical effects may last longer due to tissue distribution.
Terminal elimination half-life is 12-15 hours in adults, prolonged to 20-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Hepatic via CYP3A4 and other CYP enzymes
Phentermine: primarily renal excretion (unchanged). Topiramate: metabolized by CYP3A4 (minor), but ~70% excreted unchanged in urine. Also undergoes hydrolysis and glucuronidation.
Renal excretion of unchanged drug and metabolites; approximately 85-90% of the dose is excreted in urine within 48 hours, with less than 5% in feces.
Renal: ~70% (unchanged), Fecal: ~30% (biliary excretion of metabolites).
Approximately 20-30% bound to plasma proteins.
98% bound to albumin.
Approximately 5-10 L/kg, indicating extensive tissue distribution.
0.25-0.35 L/kg, indicating distribution primarily in extracellular fluid.
Rapidly absorbed from the gastrointestinal tract; absolute oral bioavailability is about 10-20% due to extensive first-pass hepatic metabolism.
Oral: 65-75% (first-pass metabolism); IM: 85-95%.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For moderate impairment (Cr Cl 30-59 m L/min), use with caution and consider dose reduction.
GFR >30 m L/min: No adjustment. GFR 10-30 m L/min: Use with caution, reduce dose by 50%. GFR <10 m L/min: Contraindicated.
Contraindicated in severe hepatic impairment. For Child-Pugh A or B, use with caution and consider reducing dose to 12.5 mg twice daily.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Avoid use.
Not recommended for use in children under 12 years. For adolescents 12-17 years, same adult dosing may be used under strict supervision.
Children 6-12 years: 2.5-5 mg once daily; maximum 10 mg/day. Children >12 years: Same as adult dosing.
Initiate at lower dose (12.5 mg twice daily) due to increased sensitivity and risk of adverse effects. Maximum dose 75 mg per day.
Initiate at 2.5 mg once daily; may increase to 5 mg if needed. Use with caution due to increased sensitivity.
None
No black box warning for the combination product. However, topiramate is associated with an increased risk of acute myopia and secondary angle closure glaucoma, and teratogenicity (cleft lip/palate with first-trimester exposure).
Pulmonary hypertension,Valvular heart disease,Seizures,Psychiatric disturbances,Tolerance and dependence,May impair ability to drive or operate machinery
Acute myopia and angle-closure glaucoma (topiramate); discontinue if symptoms occur.,Oligohidrosis and hyperthermia (topiramate), especially in pediatric use.,Fetal toxicity (topiramate): increased risk of oral clefts; contraception required for females of reproductive potential.,Suicidal behavior or ideation (topiramate).,Metabolic acidosis (topiramate): monitor serum bicarbonate.,Increase in heart rate (phentermine): use with caution in patients with cardiac disease.,Pulmonary hypertension (phentermine): rare but serious.,Dependence and abuse potential (phentermine, Schedule IV controlled substance).,Glaucoma angle closure risk.,Kidney stones (topiramate): hydrate to prevent.,Cognitive/neuropsychiatric effects (topiramate): difficulty with memory, concentration, or language.
Advanced arteriosclerosis,Cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Glaucoma,Agitated states,History of drug abuse,During or within 14 days of MAOI therapy
Glaucoma (angle-closure), especially with topiramate component.,Hyperthyroidism (phentermine).,Patients with a history of drug abuse (phentermine).,MAO inhibitor use within 14 days (phentermine).,Pregnancy (topiramate is teratogenic).,Breastfeeding (safety not established).,Known hypersensitivity to phentermine or topiramate.,Cardiovascular disease including arrhythmias, coronary artery disease, or uncontrolled hypertension (phentermine).,Concomitant use of other central nervous system stimulants.
No specific food interactions. However, avoid excessive caffeine intake as it may increase stimulant effects. Take with or without food; high-fat meals may delay absorption.
Avoid alcohol and caffeine-containing products. High-fat meals may delay absorption. No other specific food restrictions, but follow a reduced-calorie diet as advised by your healthcare provider.
FDA Pregnancy Category X: Teratogenic effects demonstrated in animal studies; contraindicated in pregnant women due to increased risk of fetal malformations, particularly in the first trimester. Potential for neonatal withdrawal symptoms (hyperexcitability, feeding disorders) with third trimester exposure.
First trimester: Category X. Contraindicated due to documented teratogenicity (neural tube defects, craniofacial malformations). Second/third trimester: Avoid due to risk of fetal hemorrhage and premature closure of ductus arteriosus.
Excretion in human milk unknown; risk of serious adverse reactions in nursing infants (e.g., CNS stimulation, growth suppression). Use during breastfeeding contraindicated. M/P ratio not established.
Excreted into breast milk with M/P ratio of 0.8. Contraindicated during breastfeeding due to risk of infant toxicity (renal impairment, bleeding).
No dose adjustment possible; drug contraindicated entirely during pregnancy due to known teratogenicity. If pregnancy occurs, discontinue immediately and manage with alternative therapy.
No established safe dose due to teratogenicity. If inadvertent exposure occurs, immediate discontinuation recommended. No dose adjustment is feasible given contraindication.
TENUATE DOSPAN (diethylpropion) is a schedule IV controlled substance used as an adjunct in obesity management. Avoid concurrent use with MAOIs due to hypertensive crisis risk. Monitor for tachyphylaxis and potential for abuse; limit use to short-term (up to 12 weeks). Contraindicated in patients with hyperthyroidism, glaucoma, or history of drug abuse.
BONTRIL PDM (phendimetrazine tartrate) is a sympathomimetic amine anorectic. Monitor blood pressure and heart rate due to potential increases. Avoid use in patients with history of drug abuse, cardiovascular disease, hyperthyroidism, glaucoma, or MAOI use within 14 days. Taper to avoid abrupt discontinuation. Not recommended for pediatric patients or those with hypertension.
Take exactly as prescribed; do not increase dose or frequency.,Do not crush or chew the controlled-release tablet; swallow whole.,Report any chest pain, palpitations, or shortness of breath immediately.,Avoid alcohol and other CNS stimulants.,Use caution when driving or operating machinery until you know how this drug affects you.
Take exactly as prescribed; do not exceed recommended dose.,Avoid driving or operating machinery until you know how this medication affects you.,Report chest pain, shortness of breath, or palpitations immediately.,Do not take with other stimulants or diet aids.,Inform your doctor if you become pregnant or plan to breastfeed.,Do not stop suddenly without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TENUATE DOSPAN vs BONTRIL PDM, answered by our medical review team.
TENUATE DOSPAN is a Sympathomimetic anorectic that works by Releases norepinephrine from nerve terminals in the lateral hypothalamic feeding center, reducing appetite.. BONTRIL PDM is a Sympathomimetic Anorectic that works by Phentermine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the release of norepinephrine and dopamine in the hypothalamus, reducing food intake. Topiramate is a sulfamate-substituted monosaccharide that enhances GABAergic activity and inhibits glutamatergic neurotransmission via AMPA/kainate receptors, leading to appetite suppression and increased energy expenditure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TENUATE DOSPAN and BONTRIL PDM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TENUATE DOSPAN is: 25 mg orally three times a day, 1 hour before meals, or 75 mg extended-release orally once daily in the morning.. The standard adult dose of BONTRIL PDM is: Oral: 5-10 mg once daily in the morning; maximum 20 mg/day. Oral disintegrating tablet: 5-10 mg once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TENUATE DOSPAN and BONTRIL PDM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TENUATE DOSPAN is classified as Category C. FDA Pregnancy Category X: Teratogenic effects demonstrated in animal studies; contraindicated in pregnant women due to increased risk of fetal malformations, particularly in the fi. BONTRIL PDM is classified as Category C. First trimester: Category X. Contraindicated due to documented teratogenicity (neural tube defects, craniofacial malformations). Second/third trimester: Avoid due to risk of fetal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.